1 paper2 findings
KDMAge acceleration
upin humans1HR 1.229
KDMAge acceleration is associated with cardiovascular-kidney-metabolic syndrome progression to stage 2/3 in humans (HR 1.229, 95% CI 1.180–1.280 per 1-SD increment).
“KDMAge acceleration showed corresponding HRs of 1.229 (95% CI 1.180-1.280) and 1.220 (95% CI 1.207-1.232), all P < 0.001.”
HumansUK Biobank participants initially at stage 0/1Per 1-SD incrementMedian 13.48 years
Higher biological age linked to worsening disease stages
Renal failure11 Oct 2026
PhenoAge
upin humans1HR 1.234
PhenoAge is associated with cardiovascular-kidney-metabolic syndrome progression to stage 2/3 in humans (HR 1.234, 95% CI 1.189–1.281 per 1-SD increment).
“PhenoAge acceleration was associated with both transitions [hazard ratios (HRs) 1.234, 95% confidence interval (CI) 1.189-1.281; HR 1.208, 95% CI 1.197-1.218].”
HumansUK Biobank participants initially at stage 0/1Per 1-SD incrementMedian 13.48 years
Higher biological age linked to worsening disease stages
Renal failure11 Oct 2026
Over a median 13.48 years, 2,567 UK Biobank participants progressed from stage 0 or 1 to stage 2 or 3 of the syndrome.Over a median 13.48 years, 2,567 UK Biobank participants progressed from stage 0 or 1 to stage 2 or 3 of the syndrome.